<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02066298</url>
  </required_header>
  <id_info>
    <org_study_id>AsthmaNet 007</org_study_id>
    <secondary_id>1U10HL098115</secondary_id>
    <nct_id>NCT02066298</nct_id>
  </id_info>
  <brief_title>Steroids In Eosinophil Negative Asthma</brief_title>
  <acronym>SIENA</acronym>
  <official_title>Steroids In Eosinophil Negative Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Because approximately half of all mild-moderately-severe asthma is persistently
      non-eosinophilic, it is important to determine prospectively if patients who are persistently
      non-eosinophilic differ in their benefit from inhaled corticosteroid treatment compared to
      patients who are not persistently non-eosinophilic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SIENA is a 42-week randomized, stratified, 3-period double-blind placebo-controlled crossover
      study of patients with symptomatic mild-to-moderate asthma, not already taking an inhaled
      corticosteroid, in whom the effect of &quot;medium-dose&quot; inhaled corticosteroid (ICS) will be
      compared with the effect of placebo and with a long-acting muscarinic antagonist (LMA).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pairwise Comparison of Treatments Based on Composite Measure Using Treatment Failures, Asthma Control Days, and Percent Predicted FEV1.</measure>
    <time_frame>End of 12-week treatment period</time_frame>
    <description>This composite outcome uses a hierarchical method to ascertain differences in asthma control. For each participant, treatments are first compared to see if they differ in terms of treatment failures. If one treatment results in no treatment failures and another treatment does, it is deemed the superior treatment and no further comparisons are made. If treatment superiority cannot be assigned by treatment failures, then they are compared by asthma control days (ACDs). If one treatment yields at least 31 annualized ACDs more than another, it is deemed the superior treatment. If treatment superiority still cannot be assigned by ACDs, then they are compared by percent predicted FEV1 at the end of a treatment period. If one treatment yields at least 5% greater FEV1 than another, it is deemed the superior treatment. If treatment superiority cannot be assigned by exacerbations, ACDs or FEV1, then that participant is classified as having no differential response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Failure</measure>
    <time_frame>End of 12-week treatment period</time_frame>
    <description>Treatment Failure includes:
Awakening from asthma three or more times in a two-week period or on two consecutive nights, or
Using albuterol for relief of symptoms four or more times/day for two or more consecutive days, or
Albuterol has been relieving symptoms for less than four hours after each treatment over a 12-hour period, or
Using albuterol for relief of symptoms daily for seven days, and this use exceeds two times the weekly use of albuterol in the baseline period, or
exercise induces unusual breathlessness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Asthma Control Days</measure>
    <time_frame>End of 12-week treatment period</time_frame>
    <description>Asthma Control Days (ACD) are based on patient completed electronic daily diaries, and are defined as: A day with no rescue albuterol use (pre-exercise albuterol will not be counted), no non-study asthma medications, no daytime asthma symptoms (shortness of breath, wheezing, chest tightness, phlegm/mucus rated as mild, moderate or severe, or cough rated as moderate or severe), no nighttime asthma symptoms, no unscheduled healthcare visits for asthma, and no PEF &lt; 80% of predetermined baseline. Annualized ACD are calculated as the proportion of ACD during the treatment period multiplied by 365.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume at One Second (FEV1) Percent of Predicted</measure>
    <time_frame>End of 12-week treatment period</time_frame>
    <description>FEV1, expressed as percent of predicted FEV1 based on age, sex, race, and height.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Expiratory Flow Rate</measure>
    <time_frame>End of 12-week treatment period</time_frame>
    <description>Peak expiratory flow rate is a person's maximum speed of expiration. It measures the airflow through the bronchi and thus the degree of obstruction in the airways.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Exacerbations</measure>
    <time_frame>End of 12-week treatment period</time_frame>
    <description>Asthma exacerbations are more severe episodes of acute worsening, defined by meeting one or more of the following:
FEV1 &lt;50% of baseline on 2 consecutive measurements
FEV1 &lt;40% of predicted on 2 consecutive measurements
Use of ≥ 16 puffs of &quot;as needed&quot; β-agonist per 24 hours for a period of 48 hours
Use of oral/parenteral corticosteroid due to asthma</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">295</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Mometasone then Tiotropium then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD, followed by Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone then Placebo then Tiotropium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mometasone 220mcg BID, followed by Placebo, followed by Tiotropium Respimat 5mcg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then Mometasone then Tiotropium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo, followed by Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then Tiotropium then Mometasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo, followed by Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium then Placebo then Mometasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tiotropium Respimat 5mcg QD, followed by Placebo, followed by Mometasone 220mcg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium then Mometasone then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID, followed by Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone 220mcg BID</intervention_name>
    <description>Mometasone is an ICS</description>
    <arm_group_label>Mometasone then Placebo then Tiotropium</arm_group_label>
    <arm_group_label>Mometasone then Tiotropium then Placebo</arm_group_label>
    <arm_group_label>Placebo then Mometasone then Tiotropium</arm_group_label>
    <arm_group_label>Placebo then Tiotropium then Mometasone</arm_group_label>
    <arm_group_label>Tiotropium then Mometasone then Placebo</arm_group_label>
    <arm_group_label>Tiotropium then Placebo then Mometasone</arm_group_label>
    <other_name>Asmanex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Respimat 5mcg QD</intervention_name>
    <description>Tiotropium is a LMA</description>
    <arm_group_label>Mometasone then Placebo then Tiotropium</arm_group_label>
    <arm_group_label>Mometasone then Tiotropium then Placebo</arm_group_label>
    <arm_group_label>Placebo then Mometasone then Tiotropium</arm_group_label>
    <arm_group_label>Placebo then Tiotropium then Mometasone</arm_group_label>
    <arm_group_label>Tiotropium then Mometasone then Placebo</arm_group_label>
    <arm_group_label>Tiotropium then Placebo then Mometasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Mometasone then Placebo then Tiotropium</arm_group_label>
    <arm_group_label>Mometasone then Tiotropium then Placebo</arm_group_label>
    <arm_group_label>Placebo then Mometasone then Tiotropium</arm_group_label>
    <arm_group_label>Placebo then Tiotropium then Mometasone</arm_group_label>
    <arm_group_label>Tiotropium then Mometasone then Placebo</arm_group_label>
    <arm_group_label>Tiotropium then Placebo then Mometasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physician-diagnosed asthma for at least previous 12 months.

          -  Able to perform reproducible spirometry.

          -  Baseline FEV1≥70% of predicted.

          -  Asthma confirmed either by:

               -  Beta-agonist reversibility to 4 puffs albuterol ≥ 12% OR

               -  Methacholine PC20 ≤ 16 mg/ml

          -  At least 1 of the following indications for chronic controller therapy:

               -  Asthma Symptoms &gt; 2 days/week OR

               -  Nocturnal Asthma Symptoms &gt; 2 nights/month OR

               -  Short-acting beta-agonist use for symptom control &gt; 2 days/week

          -  For participants ≥18 years of age: Ability to provide informed consent. For
             participants under 18 years of age: Ability to provide verbal or written assent and
             ability of parent to provide informed consent.

          -  Willingness, if female and able to conceive, to utilize one medically-acceptable form
             of contraception.

        Exclusion Criteria:

          -  Chronic inhaled or oral corticosteroid therapy.

          -  Use of inhaled or oral corticosteroid therapy within 6 weeks.

          -  New allergen immunotherapy within the past 3 months or anticipated changes to an
             ongoing immunotherapy regimen.

          -  Use of omalizumab within 3 months.

          -  History of:

               -  bladder-neck obstruction, urinary retention or benign prostatic hyperplasia

               -  narrow angle glaucoma

               -  significant cardiovascular disorders and arrhythmias

               -  life-threatening asthma requiring treatment with intubation or mechanical
                  ventilation within the past 5 years

          -  Respiratory tract infection within past 6 weeks.

          -  History of smoking within the past 1 year, or &gt; 10 pack-years total if ≥ 18 years of
             age, or &gt; 5 pack-years total if &lt; 18 years of age.

          -  Chronic diseases or medical conditions (other than asthma) that could put the
             participant at risk by participation, e.g. chronic diseases of the lung (other than
             asthma), heart, liver, kidney, endocrine or nervous system, or immunodeficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Busse, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona College of Medicine</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H. Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University School of Medicine</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital, Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://asthmanetresearch.org/</url>
    <description>AsthmaNet</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 10, 2014</study_first_submitted>
  <study_first_submitted_qc>February 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2014</study_first_posted>
  <results_first_submitted>March 28, 2019</results_first_submitted>
  <results_first_submitted_qc>March 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 18, 2019</results_first_posted>
  <last_update_submitted>May 16, 2019</last_update_submitted>
  <last_update_submitted_qc>May 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>dave mauger</investigator_full_name>
    <investigator_title>Principal Investigator, AsthmaNet Data Coordinating Center</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Mometasone</keyword>
  <keyword>Tiotropium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 12, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT02066298/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mometasone Then Tiotropium Then Placebo</title>
          <description>Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD, followed by Placebo
Mometasone 220mcg BID: Mometasone is an ICS
Tiotropium Respimat 5mcg QD: Tiotropium is a LMA
Placebo</description>
        </group>
        <group group_id="P2">
          <title>Mometasone Then Placebo Then Tiotropium</title>
          <description>Mometasone 220mcg BID, followed by Placebo, followed by Tiotropium Respimat 5mcg QD
Mometasone 220mcg BID: Mometasone is an ICS
Tiotropium Respimat 5mcg QD: Tiotropium is a LMA
Placebo</description>
        </group>
        <group group_id="P3">
          <title>Placebo Then Mometasone Then Tiotropium</title>
          <description>Placebo, followed by Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD
Mometasone 220mcg BID: Mometasone is an ICS
Tiotropium Respimat 5mcg QD: Tiotropium is a LMA
Placebo</description>
        </group>
        <group group_id="P4">
          <title>Placebo Then Tiotropium Then Mometasone</title>
          <description>Placebo, followed by Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID
Mometasone 220mcg BID: Mometasone is an ICS
Tiotropium Respimat 5mcg QD: Tiotropium is a LMA
Placebo</description>
        </group>
        <group group_id="P5">
          <title>Tiotropium Then Placebo Then Mometasone</title>
          <description>Tiotropium Respimat 5mcg QD, followed by Placebo, followed by Mometasone 220mcg BID
Mometasone 220mcg BID: Mometasone is an ICS
Tiotropium Respimat 5mcg QD: Tiotropium is a LMA
Placebo</description>
        </group>
        <group group_id="P6">
          <title>Tiotropium Then Mometasone Then Placebo</title>
          <description>Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID, followed by Placebo
Mometasone 220mcg BID: Mometasone is an ICS
Tiotropium Respimat 5mcg QD: Tiotropium is a LMA
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="47"/>
                <participants group_id="P6" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 1st Period</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="48"/>
                <participants group_id="P5" count="46"/>
                <participants group_id="P6" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 2nd Period</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="46"/>
                <participants group_id="P5" count="42"/>
                <participants group_id="P6" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 3rd Period</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="45"/>
                <participants group_id="P5" count="38"/>
                <participants group_id="P6" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="45"/>
                <participants group_id="P5" count="38"/>
                <participants group_id="P6" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>Mometasone Then Tiotropium Then Placebo</title>
          <description>Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD, followed by Placebo
Mometasone 220mcg BID: Mometasone is an ICS
Tiotropium Respimat 5mcg QD: Tiotropium is a LMA
Placebo</description>
        </group>
        <group group_id="B2">
          <title>Mometasone Then Placebo Then Tiotropium</title>
          <description>Mometasone 220mcg BID, followed by Placebo, followed by Tiotropium Respimat 5mcg QD
Mometasone 220mcg BID: Mometasone is an ICS
Tiotropium Respimat 5mcg QD: Tiotropium is a LMA
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Placebo Then Mometasone Then Tiotropium</title>
          <description>Placebo, followed by Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD
Mometasone 220mcg BID: Mometasone is an ICS
Tiotropium Respimat 5mcg QD: Tiotropium is a LMA
Placebo</description>
        </group>
        <group group_id="B4">
          <title>Placebo Then Tiotropium Then Mometasone</title>
          <description>Placebo, followed by Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID
Mometasone 220mcg BID: Mometasone is an ICS
Tiotropium Respimat 5mcg QD: Tiotropium is a LMA
Placebo</description>
        </group>
        <group group_id="B5">
          <title>Tiotropium Then Placebo Then Mometasone</title>
          <description>Tiotropium Respimat 5mcg QD, followed by Placebo, followed by Mometasone 220mcg BID
Mometasone 220mcg BID: Mometasone is an ICS
Tiotropium Respimat 5mcg QD: Tiotropium is a LMA
Placebo</description>
        </group>
        <group group_id="B6">
          <title>Tiotropium Then Mometasone Then Placebo</title>
          <description>Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID, followed by Placebo
Mometasone 220mcg BID: Mometasone is an ICS
Tiotropium Respimat 5mcg QD: Tiotropium is a LMA
Placebo</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="51"/>
            <count group_id="B5" value="47"/>
            <count group_id="B6" value="50"/>
            <count group_id="B7" value="295"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.3" spread="15.3"/>
                    <measurement group_id="B2" value="32.6" spread="13.8"/>
                    <measurement group_id="B3" value="33.2" spread="13.9"/>
                    <measurement group_id="B4" value="30.0" spread="14.8"/>
                    <measurement group_id="B5" value="30.8" spread="12.5"/>
                    <measurement group_id="B6" value="28.2" spread="12.9"/>
                    <measurement group_id="B7" value="31.2" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="33"/>
                    <measurement group_id="B7" value="184"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="40"/>
                    <measurement group_id="B6" value="43"/>
                    <measurement group_id="B7" value="260"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="32"/>
                    <measurement group_id="B6" value="30"/>
                    <measurement group_id="B7" value="192"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="47"/>
                    <measurement group_id="B6" value="50"/>
                    <measurement group_id="B7" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced expiratory volume at one second (FEV1) Percent of Predicted</title>
          <description>FEV1, expressed as percent of predicted FEV1 based on age, sex, race, and height.</description>
          <units>percentage of predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90.6" spread="11.5"/>
                    <measurement group_id="B2" value="91.5" spread="11.2"/>
                    <measurement group_id="B3" value="92.0" spread="11.8"/>
                    <measurement group_id="B4" value="93.8" spread="12.4"/>
                    <measurement group_id="B5" value="91.7" spread="13.6"/>
                    <measurement group_id="B6" value="91.6" spread="12.5"/>
                    <measurement group_id="B7" value="91.9" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Asthma Control Test</title>
          <description>Measure Description: Asthma Control Test: The score is calculated as the sum total of a 5-item questionnaire. Each item ranges from 1 (poor control) to 5 (good control) so that the range of the total score is 5 to 25. Scores below 20 indicate that asthma is not well controlled.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.3" spread="2.3"/>
                    <measurement group_id="B2" value="21.2" spread="2.5"/>
                    <measurement group_id="B3" value="21.1" spread="2.7"/>
                    <measurement group_id="B4" value="20.9" spread="2.2"/>
                    <measurement group_id="B5" value="20.9" spread="2.8"/>
                    <measurement group_id="B6" value="21.1" spread="2.5"/>
                    <measurement group_id="B7" value="21.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sputum differential count - Percent eosinophils</title>
          <description>Percentage of cells collected from induced sputum that are eosinophils</description>
          <units>percentage of cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.1" lower_limit="0.0" upper_limit="0.4"/>
                    <measurement group_id="B2" value="0.4" lower_limit="0.0" upper_limit="1.7"/>
                    <measurement group_id="B3" value="0.4" lower_limit="0.0" upper_limit="2.4"/>
                    <measurement group_id="B4" value="0.2" lower_limit="0.0" upper_limit="1.0"/>
                    <measurement group_id="B5" value="0.2" lower_limit="0.0" upper_limit="0.7"/>
                    <measurement group_id="B6" value="0.2" lower_limit="0.0" upper_limit="0.8"/>
                    <measurement group_id="B7" value="0.2" lower_limit="0.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood differential count - Percent eosinophils</title>
          <description>Percentage of blood cells that are eosinophils</description>
          <units>percentage of cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.3" lower_limit="1.1" upper_limit="4.1"/>
                    <measurement group_id="B2" value="4.0" lower_limit="2.0" upper_limit="5.3"/>
                    <measurement group_id="B3" value="3.0" lower_limit="1.9" upper_limit="4.7"/>
                    <measurement group_id="B4" value="3.2" lower_limit="2.0" upper_limit="5.0"/>
                    <measurement group_id="B5" value="3.0" lower_limit="1.5" upper_limit="5.0"/>
                    <measurement group_id="B6" value="2.8" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="B7" value="3.0" lower_limit="1.7" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pairwise Comparison of Treatments Based on Composite Measure Using Treatment Failures, Asthma Control Days, and Percent Predicted FEV1.</title>
        <description>This composite outcome uses a hierarchical method to ascertain differences in asthma control. For each participant, treatments are first compared to see if they differ in terms of treatment failures. If one treatment results in no treatment failures and another treatment does, it is deemed the superior treatment and no further comparisons are made. If treatment superiority cannot be assigned by treatment failures, then they are compared by asthma control days (ACDs). If one treatment yields at least 31 annualized ACDs more than another, it is deemed the superior treatment. If treatment superiority still cannot be assigned by ACDs, then they are compared by percent predicted FEV1 at the end of a treatment period. If one treatment yields at least 5% greater FEV1 than another, it is deemed the superior treatment. If treatment superiority cannot be assigned by exacerbations, ACDs or FEV1, then that participant is classified as having no differential response.</description>
        <time_frame>End of 12-week treatment period</time_frame>
        <population>For each pairwise comparison (mometasone vs. placebo and tiotropium vs. placebo), participants were required to complete both of the relevant treatment periods in order to be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Eosinophil Low</title>
            <description>Participants with sputum eosinophils &lt; 2% at study entry</description>
          </group>
          <group group_id="O2">
            <title>Eosinophil High</title>
            <description>Participants with sputum eosinophils &gt;= 2% at study entry</description>
          </group>
        </group_list>
        <measure>
          <title>Pairwise Comparison of Treatments Based on Composite Measure Using Treatment Failures, Asthma Control Days, and Percent Predicted FEV1.</title>
          <description>This composite outcome uses a hierarchical method to ascertain differences in asthma control. For each participant, treatments are first compared to see if they differ in terms of treatment failures. If one treatment results in no treatment failures and another treatment does, it is deemed the superior treatment and no further comparisons are made. If treatment superiority cannot be assigned by treatment failures, then they are compared by asthma control days (ACDs). If one treatment yields at least 31 annualized ACDs more than another, it is deemed the superior treatment. If treatment superiority still cannot be assigned by ACDs, then they are compared by percent predicted FEV1 at the end of a treatment period. If one treatment yields at least 5% greater FEV1 than another, it is deemed the superior treatment. If treatment superiority cannot be assigned by exacerbations, ACDs or FEV1, then that participant is classified as having no differential response.</description>
          <population>For each pairwise comparison (mometasone vs. placebo and tiotropium vs. placebo), participants were required to complete both of the relevant treatment periods in order to be included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mometesone superior to placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo superior to mometasone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mometesone equal to placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tiotropium superior to placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="181"/>
                    <count group_id="O2" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo superior to tiotropium</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="181"/>
                    <count group_id="O2" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tiotropium equal to placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="181"/>
                    <count group_id="O2" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that, among those participants for which either mometasone is not equal to placebo, the proportion for which mometasone is superior to placebo is equal to the proportion for which placebo is superior to mometasone. The trial was designed to provide power of 0.85 for a 0.20 difference between the proportions being compared at a significance level of 0.025.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>exact binomial test</method>
            <method_desc>a priori threshold for significance was 0.025</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that, among those participants for which either tiotropium is not equal to placebo, the proportion for which tiotropium is superior to placebo is equal to the proportion for which placebo is superior to tiotropium. The trial was designed to provide power of 0.85 for a 0.20 difference between the proportions being compared at a significance level of 0.025.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.029</p_value>
            <p_value_desc>a priori threshold for significance was 0.025</p_value_desc>
            <method>exact binomial test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that, among those participants for which either mometasone is not equal to placebo, the proportion for which mometasone is superior to placebo is equal to the proportion for which placebo is superior to mometasone. This was an exploratory analysis and there were no power considerations.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>this analysis is considered exploratory</p_value_desc>
            <method>exact binomial test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that, among those participants for which either tiotropium is not equal to placebo, the proportion for which tiotropium is superior to placebo is equal to the proportion for which placebo is superior to tiotropium. This was an exploratory analysis and there were no power considerations.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.45</p_value>
            <p_value_desc>this analysis is considered exploratory</p_value_desc>
            <method>exact binomial test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Failure</title>
        <description>Treatment Failure includes:
Awakening from asthma three or more times in a two-week period or on two consecutive nights, or
Using albuterol for relief of symptoms four or more times/day for two or more consecutive days, or
Albuterol has been relieving symptoms for less than four hours after each treatment over a 12-hour period, or
Using albuterol for relief of symptoms daily for seven days, and this use exceeds two times the weekly use of albuterol in the baseline period, or
exercise induces unusual breathlessness</description>
        <time_frame>End of 12-week treatment period</time_frame>
        <population>participants who completed the treatment period with data to evaluate treatment failure outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The placebo treatment period for all participants.</description>
          </group>
          <group group_id="O2">
            <title>Mometasone 220mcg BID</title>
            <description>The mometasone treatment period for all participants. Mometasone administered 220mcg BID</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat 5mcg QD</title>
            <description>The tiotropium treatment period for all participants. Tiotropium administered 5mcg QD</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Failure</title>
          <description>Treatment Failure includes:
Awakening from asthma three or more times in a two-week period or on two consecutive nights, or
Using albuterol for relief of symptoms four or more times/day for two or more consecutive days, or
Albuterol has been relieving symptoms for less than four hours after each treatment over a 12-hour period, or
Using albuterol for relief of symptoms daily for seven days, and this use exceeds two times the weekly use of albuterol in the baseline period, or
exercise induces unusual breathlessness</description>
          <population>participants who completed the treatment period with data to evaluate treatment failure outcome</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Asthma Control Days</title>
        <description>Asthma Control Days (ACD) are based on patient completed electronic daily diaries, and are defined as: A day with no rescue albuterol use (pre-exercise albuterol will not be counted), no non-study asthma medications, no daytime asthma symptoms (shortness of breath, wheezing, chest tightness, phlegm/mucus rated as mild, moderate or severe, or cough rated as moderate or severe), no nighttime asthma symptoms, no unscheduled healthcare visits for asthma, and no PEF &lt; 80% of predetermined baseline. Annualized ACD are calculated as the proportion of ACD during the treatment period multiplied by 365.</description>
        <time_frame>End of 12-week treatment period</time_frame>
        <population>participants who completed the treatment period with data to evaluate asthma control days</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The placebo treatment period for all participants</description>
          </group>
          <group group_id="O2">
            <title>Mometasone 220mcg BID</title>
            <description>The mometasone treatment period for all participants. Mometasone administered 220mcg BID</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat 5mcg QD</title>
            <description>The tiotropium treatment period for all participants. Tiotropium administered 5mcg QD</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Asthma Control Days</title>
          <description>Asthma Control Days (ACD) are based on patient completed electronic daily diaries, and are defined as: A day with no rescue albuterol use (pre-exercise albuterol will not be counted), no non-study asthma medications, no daytime asthma symptoms (shortness of breath, wheezing, chest tightness, phlegm/mucus rated as mild, moderate or severe, or cough rated as moderate or severe), no nighttime asthma symptoms, no unscheduled healthcare visits for asthma, and no PEF &lt; 80% of predetermined baseline. Annualized ACD are calculated as the proportion of ACD during the treatment period multiplied by 365.</description>
          <population>participants who completed the treatment period with data to evaluate asthma control days</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179" spread="137"/>
                    <measurement group_id="O2" value="186" spread="141"/>
                    <measurement group_id="O3" value="176" spread="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume at One Second (FEV1) Percent of Predicted</title>
        <description>FEV1, expressed as percent of predicted FEV1 based on age, sex, race, and height.</description>
        <time_frame>End of 12-week treatment period</time_frame>
        <population>participants who completed the treatment period and were able to provide FEV1 measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Eosinophil Low - Placebo</title>
            <description>The placebo treatment period for all participants</description>
          </group>
          <group group_id="O2">
            <title>Mometasone 220mcg BID</title>
            <description>The mometasone treatment period for all participants. Mometasone administered 220mcg BID</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat 5mcg QD</title>
            <description>The tiotropium treatment period for all participants. Tiotropium administered 5mcg QD</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume at One Second (FEV1) Percent of Predicted</title>
          <description>FEV1, expressed as percent of predicted FEV1 based on age, sex, race, and height.</description>
          <population>participants who completed the treatment period and were able to provide FEV1 measurements</population>
          <units>percentage of predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="247"/>
                <count group_id="O3" value="252"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" spread="14"/>
                    <measurement group_id="O2" value="94" spread="13"/>
                    <measurement group_id="O3" value="95" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Expiratory Flow Rate</title>
        <description>Peak expiratory flow rate is a person's maximum speed of expiration. It measures the airflow through the bronchi and thus the degree of obstruction in the airways.</description>
        <time_frame>End of 12-week treatment period</time_frame>
        <population>participants who completed the treatment period and were able to provide FEV1 measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The placebo treatment period for all participants</description>
          </group>
          <group group_id="O2">
            <title>Mometasone 220mcg BID</title>
            <description>The mometasone treatment period for all participants. Mometasone administered 220mcg BID</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat 5mcg QD</title>
            <description>The tiotropium treatment period for all participants. Tiotropium administered 5mcg QD</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Expiratory Flow Rate</title>
          <description>Peak expiratory flow rate is a person's maximum speed of expiration. It measures the airflow through the bronchi and thus the degree of obstruction in the airways.</description>
          <population>participants who completed the treatment period and were able to provide FEV1 measurements</population>
          <units>liters per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="249"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="476" spread="117"/>
                    <measurement group_id="O2" value="485" spread="117"/>
                    <measurement group_id="O3" value="497" spread="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Exacerbations</title>
        <description>Asthma exacerbations are more severe episodes of acute worsening, defined by meeting one or more of the following:
FEV1 &lt;50% of baseline on 2 consecutive measurements
FEV1 &lt;40% of predicted on 2 consecutive measurements
Use of ≥ 16 puffs of &quot;as needed&quot; β-agonist per 24 hours for a period of 48 hours
Use of oral/parenteral corticosteroid due to asthma</description>
        <time_frame>End of 12-week treatment period</time_frame>
        <population>participants who completed the treatment period with data to evaluate exacerbations</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The placebo treatment period for all participants</description>
          </group>
          <group group_id="O2">
            <title>Mometasone 220mcg BID</title>
            <description>The mometasone treatment period for all participants. Mometasone administered 220mcg BID</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat 5mcg QD</title>
            <description>The tiotropium treatment period for all participants. Tiotropium administered 5mcg QD</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Exacerbations</title>
          <description>Asthma exacerbations are more severe episodes of acute worsening, defined by meeting one or more of the following:
FEV1 &lt;50% of baseline on 2 consecutive measurements
FEV1 &lt;40% of predicted on 2 consecutive measurements
Use of ≥ 16 puffs of &quot;as needed&quot; β-agonist per 24 hours for a period of 48 hours
Use of oral/parenteral corticosteroid due to asthma</description>
          <population>participants who completed the treatment period with data to evaluate exacerbations</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Each participant was followed over the course of three 12-week treatment periods for a total of 36 weeks. The adverse events recorded below are reported at the treatment period level and represent 12 weeks of &quot;at risk&quot; exposure time.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>The placebo treatment period for all participants</description>
        </group>
        <group group_id="E2">
          <title>Mometasone 220mcg BID</title>
          <description>The mometasone treatment period for all participants. Mometasone administered 220mcg BID</description>
        </group>
        <group group_id="E3">
          <title>Tiotropium Respimat 5mcg QD</title>
          <description>The tiotropium treatment period for all participants. Tiotropium administered 5mcg QD</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>ICD-9</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="275"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Partial bowel obstruction.</sub_title>
                <counts group_id="E1" subjects_at_risk="276"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Acute appendicitis without mention of peritonitis</sub_title>
                <counts group_id="E1" subjects_at_risk="276"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>closed fracture of lower end of humerus</sub_title>
                <counts group_id="E1" subjects_at_risk="276"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hydatidiform mole</sub_title>
                <counts group_id="E1" subjects_at_risk="276"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>malignant neoplasm of skin of other and unspecified parts of face</sub_title>
                <counts group_id="E1" subjects_at_risk="276"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>pregnancy</sub_title>
                <counts group_id="E1" subjects_at_risk="276"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title vocab="ICS-9">Unspecified nonpsychotic mental disorder</sub_title>
                <counts group_id="E1" subjects_at_risk="276"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Adjustment disorder with depressed mood</sub_title>
                <counts group_id="E1" subjects_at_risk="276"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>ICD-9</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="276"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="275"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute nasopharyngitis</sub_title>
                <counts group_id="E1" events="42" subjects_affected="37" subjects_at_risk="276"/>
                <counts group_id="E2" events="38" subjects_affected="33" subjects_at_risk="275"/>
                <counts group_id="E3" events="37" subjects_affected="29" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Acute URI not otherwise specified</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="276"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="275"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Mauger</name_or_title>
      <organization>Penn State University</organization>
      <phone>717-531-7178</phone>
      <email>dmauger@psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

